Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).

Kerstin Wimmer,Monika Sachet,H. Birnleitner,Ruth Exner,Martin Filipits,Michael Gnant,Florian Fitzal,Rudolf Oehler

Differential effects of epirubicin and docetaxel on the immune system in patients with breast cancer (BC).

2020

Kerstin Wimmer
Monika Sachet
H. Birnleitner
Ruth Exner
Martin Filipits
Michael Gnant
Florian Fitzal
Rudolf Oehler

588Background: Neoadjuvant chemotherapy (NAC) with epirubicin/cyclophosphamid (EC) followed by docetaxel (D) is currently a standard of care therapy in women with early, high-risk breast cancer (BC...

Keywords:

differential effects
Oncology
Epirubicin
standard of care
Chemotherapy
Breast cancer
in patient
Immune system
Pathology
Internal medicine
Docetaxel
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations